We serve Chemical Name:6-(oxiran-2-yl)-7-oxabicyclo[4.1.0]heptane CAS:4223-10-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![6-(oxiran-2-yl)-7-oxabicyclo[4.1.0]heptane](https://a.dearchem.com/CAS2/4223-10-3.png)
Chemical Name:6-(oxiran-2-yl)-7-oxabicyclo[4.1.0]heptane
CAS.NO:4223-10-3
Synonyms:EINECS 224-171-8;vinylcyclohexene dioxide;4-vinyl-cyclohexene diepoxide;Vinylcyclohexene diepoxide
Molecular Formula:C8H12O2
Molecular Weight:140.18000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:216.5ºC at 760 mmHg
Density:1.286g/cm3
Index of Refraction:1.576
PSA:25.06000
Exact Mass:140.08400
LogP:1.09680
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 224-171-8 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Vinylcyclohexene diepoxide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 224-171-8 Use and application,EINECS 224-171-8 technical grade,usp/ep/jp grade.
Related News: The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. 8-(3-dimethylamino-propylamino)-1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione manufacturers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. 2-Heptenal, 6-methyl-2-(1-methylpropyl)-, (Z)- suppliers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. (8R,9S,10R,13S,14S,17S)-13-ethyl-3-(methoxyimino)-3′-methyl-1,2,3,6,7,8,9,10,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,5′-oxazolidin]-2′-one vendor & factory “In the past few years, the pharmaceutical industry has seen rapid growth driven by the growth of small molecules’ innovations, complex APIs and the increasing need to optimize available resources. ,Zynteglo was granted conditional marketing authorisation in May 2019. The conditional authorisation means that there is more evidence to come about the medicine, which the company will provide. EMA regularly reviews new information that becomes available.
